| Abstract | The results of 3 large randomized trials of activated factor X inhibitors, for the prevention of venous thromboembolism, recently became available. Similar data for orally active thrombin inhibitors is also available from recent trials. In this review, we attempt to provide a balanced perspective on the relative merits and demerits of the new, orally active anticoagulants, and speculate on the future of these agents in clinical practice. |
| Authors | Ganesan Karthikeyan, John W Eikelboom, Jack Hirsh
(Affiliation: Department of Medicine, McMaster University, Hamilton, ON, Canada. karthik2010 at gmail.com)
|
| Journal | Polskie archiwum medycyny wewnȩtrznej
(Pol Arch Med Wewn)
2009 Jan-Feb
Vol. 119
Issue 1-2
Pg. 53-8
ISSN: 0032-3772 [Print] Poland |
| PMID | 19341179
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Anticoagulants
- Benzimidazoles
- Morpholines
- Pyrazoles
- Pyridines
- Pyridones
- Thiophenes
- apixaban
- rivaroxaban
- dabigatran etexilate
- Factor Xa
|
| Topics |
- Administration, Oral
- Anticoagulants
(administration & dosage)
- Benzimidazoles
(administration & dosage)
- Drug Administration Schedule
- Factor Xa
(antagonists & inhibitors)
- Humans
- Morpholines
(administration & dosage)
- Pyrazoles
(administration & dosage)
- Pyridines
(administration & dosage)
- Pyridones
(administration & dosage)
- Randomized Controlled Trials as Topic
- Thiophenes
(administration & dosage)
- Venous Thromboembolism
(prevention & control)
|
